Quick Answer
HCW Biologics Inc. reported Cash and Equivalents of $1.95 million for fiscal year 2025.
HCW Biologics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $1.95M | -58.2% |
| 2024 | $4.67M | +30.0% |
| 2023 | $3.60M | -83.9% |
| 2022 | $22.33M | +90.3% |
| 2021 | $11.73M | +38.7% |
| 2020 | $8.46M | +15.0% |
| 2019 | $7.36M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.10M | +9.9% | -55.0% |
| June 30, 2025 | $2.44M | +110.0% | +120.2% |
| March 31, 2025 | $1.11M | -72.9% | -76.3% |
| December 31, 2024 | $4.67M | +30.0% | +368.3% |
| September 30, 2024 | $998.2K | -91.1% | -14.0% |
| June 30, 2024 | $1.16M | -84.4% | -71.6% |
| March 31, 2024 | $4.08M | -77.8% | +13.6% |
| December 31, 2023 | $3.60M | -83.9% | -68.0% |
- HCW Biologics Inc. showed a decrease of -58.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, HCW Biologics Inc.’s cash and equivalents has declined by 73.5% (from $7.36 million to $1.95 million).
- The most recent figure is from HCW Biologics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: